Product: Cytochrome P450 19A1 Antibody
Catalog: AF5229
Description: Rabbit polyclonal antibody to Cytochrome P450 19A1
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Bovine, Sheep, Rabbit, Dog
Mol.Wt.: 55 kDa; 58kD(Calculated).
Uniprot: P11511
RRID: AB_2837715

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Bovine(100%), Sheep(100%), Rabbit(100%), Dog(100%)
Clonality:
Polyclonal
Specificity:
Cytochrome P450 19A1 Antibody detects endogenous levels of total Cytochrome P450 19A1.
RRID:
AB_2837715
Cite Format: Affinity Biosciences Cat# AF5229, RRID:AB_2837715.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

ARO; ARO1; Aromatase; CP19A_HUMAN; CPV1; CYAR; CYP19; Cyp19a1; CYPXIX; Cytochrome P-450AROM; Cytochrome P450 19A1; Cytochrome P450, family 19, subfamily A, polypeptide 1; Cytochrome P450, subfamily XIX (aromatization of androgens); Estrogen synthase; Estrogen synthetase; Flavoprotein linked monooxygenase; MGC104309; Microsomal monooxygenase; OTTHUMP00000162543; OTTHUMP00000198350; P 450AROM;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P11511 CP19A_HUMAN:

Widely expressed, including in adult and fetal brain, placenta, skin fibroblasts, adipose tissue and gonads.

Description:
Defects in CYP19A1 are a cause of aromatase excess syndrome (AEXS) [MIM:139300]; also known as familial gynecomastia. AEXS is characterized by an estrogen excess due to an increased aromatase activity. Defects in CYP19A1 are the cause of aromatase deficiency (AROD) [MIM:107910]. AROD is a rare disease in which fetal androgens are not converted into estrogens due to placental aromatase deficiency.
Sequence:
MVLEMLNPIHYNITSIVPEAMPAATMPVLLLTGLFLLVWNYEGTSSIPGPGYCMGIGPLISHGRFLWMGIGSACNYYNRVYGEFMRVWISGEETLIISKSSSMFHIMKHNHYSSRFGSKLGLQCIGMHEKGIIFNNNPELWKTTRPFFMKALSGPGLVRMVTVCAESLKTHLDRLEEVTNESGYVDVLTLLRRVMLDTSNTLFLRIPLDESAIVVKIQGYFDAWQALLIKPDIFFKISWLYKKYEKSVKDLKDAIEVLIAEKRRRISTEEKLEECMDFATELILAEKRGDLTRENVNQCILEMLIAAPDTMSVSLFFMLFLIAKHPNVEEAIIKEIQTVIGERDIKIDDIQKLKVMENFIYESMRYQPVVDLVMRKALEDDVIDGYPVKKGTNIILNIGRMHRLEFFPKPNEFTLENFAKNVPYRYFQPFGFGPRGCAGKYIAMVMMKAILVTLLRRFHVKTLQGQCVESIQKIHDLSLHPDETKNMLEMIFTPRNSDRCLEH

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Bovine
100
Sheep
100
Dog
100
Rabbit
100
Xenopus
73
Chicken
64
Horse
55
Pig
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P11511 As Substrate

Site PTM Type Enzyme
S118 Phosphorylation
T162 Phosphorylation
S167 Phosphorylation
T201 Phosphorylation
Y220 Phosphorylation
Y241 Phosphorylation
Y361 Phosphorylation P12931 (SRC)
T392 Phosphorylation
Y441 Phosphorylation
T484 Phosphorylation
S497 Phosphorylation

Research Backgrounds

Function:

A cytochrome P450 monooxygenase that catalyzes the conversion of C19 androgens, androst-4-ene-3,17-dione (androstenedione) and testosterone to the C18 estrogens, estrone and estradiol, respectively. Catalyzes three successive oxidations of C19 androgens: two conventional oxidations at C19 yielding 19-hydroxy and 19-oxo/19-aldehyde derivatives, followed by a third oxidative aromatization step that involves C1-beta hydrogen abstraction combined with cleavage of the C10-C19 bond to yield a phenolic A ring and formic acid. Alternatively, the third oxidative reaction yields a 19-norsteroid and formic acid. Converts dihydrotestosterone to delta1,10-dehydro 19-nordihydrotestosterone and may play a role in homeostasis of this potent androgen. Also displays 2-hydroxylase activity toward estrone. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase).

PTMs:

Phosphorylated in vitro by PKA and PKG/PRKG1. These phosphorylations inhibit the catalytic activity as measured by estrone synthesis from androstenedione (36% decrease for PKA and 30% for PKG/PRKG1).

Subcellular Location:

Endoplasmic reticulum membrane>Multi-pass membrane protein. Microsome membrane>Multi-pass membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Widely expressed, including in adult and fetal brain, placenta, skin fibroblasts, adipose tissue and gonads.

Family&Domains:

Belongs to the cytochrome P450 family.

Research Fields

· Metabolism > Lipid metabolism > Steroid hormone biosynthesis.

· Metabolism > Global and overview maps > Metabolic pathways.

· Organismal Systems > Endocrine system > Ovarian steroidogenesis.

References

1). Exosomes Derived from Yak Follicular Fluid Increase 2-Hydroxyestradiol Secretion by Activating Autophagy in Cumulus Cells. Animals, 2022 (PubMed: 36428401) [IF=3.0]

Application: IF/ICC    Species: Human    Sample: YCCs

Figure 5. Yak follicular fluid exosomes could increase 2-OHE2 secretion in YCCs. (A) Immunofluorescence staining of CYP19A1 and CYP1A1 proteins in YCCs. Scale bar represents 50 μm. (B) Expression of 2-OHE2 secretion-related genes CYP17A1 (B1), CYP19A1 (B2), CYP1A1 (B3) and CYP1B1 (B4) in YCCs using the qPCR assay. (C) Western blot analysis of the protein expression in YCCs (C: Control, E: Yak follicular fluid exosomes) (See Figure S2). (D) ELISA kit analyses of the concentrations of estradiol (pg/mL) in the cell supernatant. (E) Quantitative Western blot results for CYP17A1 (E1), CYP19A1 (E2), CYP1A1 (E3) and CYP1B1 (E4). Data are expressed as the mean ± SD. n = 6. NS means no significant difference. * p < 0.05 and ** p < 0.01 indicate significant differences between the yak follicular fluid exosome treatments and the control.

Application: WB    Species: Human    Sample: YCCs

Figure 5. Yak follicular fluid exosomes could increase 2-OHE2 secretion in YCCs. (A) Immunofluorescence staining of CYP19A1 and CYP1A1 proteins in YCCs. Scale bar represents 50 μm. (B) Expression of 2-OHE2 secretion-related genes CYP17A1 (B1), CYP19A1 (B2), CYP1A1 (B3) and CYP1B1 (B4) in YCCs using the qPCR assay. (C) Western blot analysis of the protein expression in YCCs (C: Control, E: Yak follicular fluid exosomes) (See Figure S2). (D) ELISA kit analyses of the concentrations of estradiol (pg/mL) in the cell supernatant. (E) Quantitative Western blot results for CYP17A1 (E1), CYP19A1 (E2), CYP1A1 (E3) and CYP1B1 (E4). Data are expressed as the mean ± SD. n = 6. NS means no significant difference. * p < 0.05 and ** p < 0.01 indicate significant differences between the yak follicular fluid exosome treatments and the control.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.